Revvity RVTY Life Sciences — D&A
Discontinued — last reported Q1 '26
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Revvity's life sciences — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Revvity's life sciences — D&A?
- Revvity (RVTY) reported life sciences — D&A of $9.91M in Q1 2026.
- How has Revvity's life sciences — D&A changed year-over-year?
- Revvity's life sciences — D&A increased by 37.9% year-over-year, from $7.19M to $9.91M.
- What is the long-term trend for Revvity's life sciences — D&A?
- Over 2 years (2021 to 2023), Revvity's life sciences — D&A has grown at a 70.8% compound annual growth rate (CAGR), from $94.7M to $276.12M.
- What does life sciences — D&A mean?
- The non-cash expense representing the aging of assets used by the Life Sciences segment.
- How do you interpret life sciences — D&A?
- High levels relative to revenue may indicate a capital-intensive business model or significant recent intangible asset acquisitions.
- How does life sciences — D&A compare across companies?
- Standard non-cash expense reported by all companies with significant property, plant, and equipment or acquired intangibles.